{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:31:02Z","timestamp":1759541462954,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,8,18]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Febuxostat is a non-purine xanthine oxidase inhibitor primarily used to treat gout and hyperuricaemia. Although it has a better safety profile compared to allopurinol, febuxostat has been associated with rare cases of drug-induced liver injury. We present a case of a man in his late 50s who developed liver injury after switching from allopurinol to febuxostat for gout management. The patient experienced fatigue, nausea, jaundice and had notably elevated aminotransferase activities. A liver biopsy revealed moderate acute hepatocellular injury. After discontinuing febuxostat, the liver tests did not improve for 1\u2009month until treatment with prednisone. This case adds to the existing literature on febuxostat-induced liver injury and highlights the variability in clinical and histological manifestations. It also emphasises the importance of monitoring liver tests in patients taking febuxostat.<\/jats:p>","DOI":"10.1136\/bcr-2025-266332","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T20:50:14Z","timestamp":1756673414000},"page":"e266332","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Febuxostat-induced hepatocellular injury"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-5190","authenticated-orcid":false,"given":"Joanne","family":"Lin","sequence":"first","affiliation":[{"name":"Hoag Digestive Health Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA"},{"name":"Gastroenterology\/Hepatology, UCSF, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Braxton","sequence":"additional","affiliation":[{"name":"Pathology, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tse-Ling","family":"Fong","sequence":"additional","affiliation":[{"name":"Hoag Digestive Health Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"2025083113500550000_18.8.e266332.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.031"},{"key":"2025083113500550000_18.8.e266332.2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H121"},{"key":"2025083113500550000_18.8.e266332.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"2025083113500550000_18.8.e266332.4","unstructured":"Qurie A , Preuss CV , Allopurinol MR . Allopurinol [internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499942\/ [Accessed 18 Sep 2024]."},{"key":"2025083113500550000_18.8.e266332.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710895"},{"key":"2025083113500550000_18.8.e266332.6","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645080-00005"},{"key":"2025083113500550000_18.8.e266332.7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/CIA.S5476","article-title":"Management of hyperuricemia in gout: focus on febuxostat","volume":"5","author":"Reinders","year":"2010","journal-title":"Clin Interv Aging"},{"key":"2025083113500550000_18.8.e266332.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180761"},{"key":"2025083113500550000_18.8.e266332.9","unstructured":"Febuxostat . LiverTox: clinical and research information on drug-induced liver injury [internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548645\/ [Accessed 18 Sep 2024]."},{"key":"2025083113500550000_18.8.e266332.10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/hep.28403","article-title":"Drug-Induced Liver Injury Network (DILIN). Febuxostat-induced acute liver injury","volume":"63","author":"Bohm","year":"2016","journal-title":"Hepatology"},{"key":"2025083113500550000_18.8.e266332.11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s13730-014-0109-2","article-title":"Acute severe liver dysfunction induced by febuxostat in a patient undergoing hemodialysis","volume":"3","author":"Ito","year":"2014","journal-title":"CEN Case Rep"},{"key":"2025083113500550000_18.8.e266332.12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/01480545.2023.2178451","article-title":"Two cases report of febuxostat-induced acute liver injury: acute heart failure as a probable risk factor?","volume":"47","author":"Zhu","year":"2024","journal-title":"Drug Chem Toxicol"},{"key":"2025083113500550000_18.8.e266332.13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40264-018-0654-2","article-title":"Drug-induced liver injury: why is the roussel uclaf causality assessment method (rucam) still used 25 years after its launch?","volume":"41","author":"Danan","year":"2018","journal-title":"Drug Saf"},{"key":"2025083113500550000_18.8.e266332.14","unstructured":"Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury . LiverTox: clinical and research information on drug-induced liver injury [internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548272\/ [Accessed 18 Sep 2024]."},{"key":"2025083113500550000_18.8.e266332.15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025083113500550000_18.8.e266332.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.05.043"},{"key":"2025083113500550000_18.8.e266332.17","doi-asserted-by":"crossref","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"2025083113500550000_18.8.e266332.18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0029-1233532","article-title":"Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future","volume":"29","author":"Wiegard","year":"2009","journal-title":"Semin Liver Dis"},{"key":"2025083113500550000_18.8.e266332.19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1284434"},{"key":"2025083113500550000_18.8.e266332.20","unstructured":"FDA Adverse Event Reporting System (FAERS) public dashboard . Center for drug evaluation and research [internet]. Silver Spring (MD): U.S. Food and Drug Administration. Available: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard [Accessed 18 Sep 2024]."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-266332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T20:50:16Z","timestamp":1756673416000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-266332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,31]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bcr-2025-266332"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-266332","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}